Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) has provided an announcement.
OncoSil Medical Limited has announced that the Federal Joint Committee in Germany has initiated a tender process to select a Contract Research Organisation for a study on the OncoSil™ device. This study will evaluate the device’s effectiveness in combination with chemotherapy for treating unresectable, locally advanced pancreatic cancer. This development is a significant step towards potential inclusion in German treatment guidelines and the statutory health insurance system, which could impact the company’s market positioning and stakeholder interests.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a company specializing in cancer treatment devices, particularly the OncoSil™ brachytherapy device used for treating locally advanced unresectable pancreatic cancer. The device delivers targeted intratumoral placement of Phosphorous-32 in combination with chemotherapy. It has received breakthrough device designation in the EU, UK, and US, and is approved for sale in over 30 countries.
Technical Sentiment Signal: Buy
Current Market Cap: A$23.03M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.